Related Experiment Videos
Combined therapeutic strategy for multiple coronary thromboemboli
1Hemodynamic Interventional Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Insights
A woman with mitral valve disease experienced acute myocardial infarction due to coronary thromboemboli. A combined treatment of intracoronary thrombolysis, abciximab, and angioplasty successfully restored blood flow without complications.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Medicine
Background:
- Mitral valvular disease can predispose patients to complex cardiovascular events.
- Acute myocardial infarction in this context presents unique diagnostic and therapeutic challenges.
- Coronary thromboembolism is a rare but serious complication requiring prompt intervention.
Observation:
- A female patient with pre-existing mitral valvular disease presented with acute myocardial infarction.
- Symptoms included recurrent chest pain and pulmonary edema, indicative of acute cardiac distress.
- Coronary angiography revealed multiple coronary thromboemboli as the cause of infarction.
Findings:
- A multi-modal treatment strategy was employed, including intracoronary thrombolysis.
- Administration of a platelet glycoprotein IIb/IIIa antagonist (abciximab) was part of the intervention.
- Percutaneous transluminal coronary angioplasty was utilized to disrupt the coronary thrombi.
Implications:
- The combined therapeutic approach rapidly achieved clinical and angiographic evidence of coronary reperfusion.
- This strategy proved effective in managing acute myocardial infarction secondary to coronary thromboemboli in a patient with mitral valve disease.
- No adverse bleeding complications were observed, suggesting a favorable safety profile for this combined intervention.
Abstract:
A female with mitral valvular disease presented an acute myocardial infarction. She suddenly complained of recurrent chest pain with symptoms of pulmonary edema. The angiogram evidenced multiple coronary thromboemboli. A combined strategy using intracoronary thrombolysis, a platelet glycoprotein IIb/IIIa antagonist (abciximab) and percutaneous transluminal coronary angioplasty to help disrupt the thrombus was performed. Clinical and angiographic signs of coronary reperfusion were rapidly achieved. No bleeding complications appeared.